worldwid
million
peopl
hepat
c
viru
hcv
infect
chronic
infect
hcv
lead
liver
diseas
cirrhosi
hepatocarcinoma
major
reason
liver
transplant
current
standard
treatment
hepat
c
reli
combin
interferona
ribavirin
immun
booster
gener
inhibitor
viru
replic
respect
associ
seriou
side
effect
includ
hemolyt
anaemia
depress
fatigu
flulik
symptom
birth
defect
standard
care
frequent
ineffect
clear
hcv
infect
viru
often
surviv
thrive
even
treatment
develop
directact
antivir
agent
hepat
c
treatment
studi
focus
discoveri
inhibitor
viral
enzym
specif
nonstructur
protein
serin
proteas
rnadepend
rna
polymeras
rdrp
last
year
new
drug
treat
hepat
c
telaprevir
vertex
boceprevir
merck
serin
proteas
inhibitor
approv
us
food
drug
administr
fda
drug
candid
target
proteas
rdrp
current
clinic
trial
although
phase
iii
clinic
trial
telaprevir
boceprevir
show
notabl
increas
cure
rate
nearli
everi
patient
still
suffer
least
one
side
effect
new
therapi
c
addit
hcv
strong
drug
resist
due
high
mutabl
thu
therapeut
option
urgent
need
treat
hcv
infect
effect
ctermin
two
third
hcv
form
helicas
abil
unwind
doublestrand
dna
dsdna
singlestrand
dna
ssdna
fuel
nucleosid
triphosph
ntp
hydrolyz
ntpase
domain
helicas
one
essenti
enzym
hcv
along
serin
proteas
rdrp
process
hcv
protein
replic
hcv
thu
inhibit
helicas
activ
import
strategi
treat
hcv
infect
howev
discoveri
helicas
inhibitor
much
slower
compar
hcv
drug
target
date
class
helicas
inhibitor
report
partli
highthroughput
screen
yield
success
hit
c
exampl
compound
discov
nih
screen
base
molecularbeaconbas
helicas
assay
mbha
show
poor
activ
cell
turn
interfer
assay
even
though
anoth
mbha
screen
identifi
compound
inhibit
rna
replic
cell
therefor
urgent
need
new
assay
measur
helicas
activ
suitabl
highthroughput
screen
herein
develop
multiplex
helicas
assay
base
graphen
oxid
go
highthroughput
screen
inhibitor
hcv
helicas
sever
acut
respiratori
syndrom
coronaviru
sar
cov
helicas
previous
report
gobas
helicas
assay
goha
reli
preferenti
bind
ssdna
dsdna
go
surfac
subsequ
quench
fluoresc
label
ssdna
energi
transfer
dye
go
valid
assay
use
sar
cov
helicas
herein
show
goha
use
measur
activ
hcv
helicas
sar
cov
helicas
singl
mix
solut
use
two
distinct
dna
substrat
tether
differ
fluorophor
furthermor
multiplex
highthroughput
screen
discov
highli
select
smallmolecul
inhibitor
helicas
figur
one
round
screen
chemic
librari
use
multiplex
goha
mgoha
reveal
three
class
inhibitorsspecif
inhibitor
hcv
helicas
specif
inhibitor
sar
cov
helicas
gener
inhibitor
helicas
date
go
use
develop
variou
biosensor
enzym
assay
concern
heterogen
chemic
structur
physic
dimens
go
nonspecif
bind
biomolecul
go
hamper
applic
gobas
worldwid
million
peopl
hepat
c
viru
hcv
infect
chronic
infect
hcv
lead
liver
diseas
cirrhosi
hepatocarcinoma
major
reason
liver
transplant
current
standard
treatment
hepat
c
reli
combin
interferona
ribavirin
immun
booster
gener
inhibitor
viru
replic
respect
associ
seriou
side
effect
includ
hemolyt
anaemia
depress
fatigu
flulik
symptom
birth
defect
standard
care
frequent
ineffect
clear
hcv
infect
viru
often
surviv
thrive
even
treatment
develop
directact
antivir
agent
hepat
c
treatment
studi
focus
discoveri
inhibitor
viral
enzym
specif
nonstructur
protein
serin
proteas
rnadepend
rna
polymeras
rdrp
last
year
new
drug
treat
hepat
c
telaprevir
vertex
boceprevir
merck
serin
proteas
inhibitor
approv
us
food
drug
administr
fda
drug
candid
target
proteas
rdrp
current
clinic
trial
although
phase
iii
clinic
trial
telaprevir
boceprevir
show
notabl
increas
cure
rate
nearli
everi
patient
still
suffer
least
one
side
effect
new
therapi
c
addit
hcv
strong
drug
resist
due
high
mutabl
thu
therapeut
option
urgent
need
treat
hcv
infect
effect
ctermin
two
third
hcv
form
helicas
abil
unwind
doublestrand
dna
dsdna
singlestrand
dna
ssdna
fuel
nucleosid
triphosph
ntp
hydrolyz
ntpase
domain
helicas
one
essenti
enzym
hcv
along
serin
proteas
rdrp
process
hcv
protein
replic
hcv
thu
inhibit
helicas
activ
import
strategi
treat
hcv
infect
howev
discoveri
helicas
inhibitor
much
slower
compar
hcv
drug
target
date
class
helicas
inhibitor
report
partli
highthroughput
screen
yield
success
hit
c
exampl
compound
discov
nih
screen
base
molecularbeaconbas
helicas
assay
mbha
show
poor
activ
cell
turn
interfer
assay
even
though
anoth
mbha
screen
identifi
compound
inhibit
rna
replic
cell
therefor
urgent
need
new
assay
measur
helicas
activ
suitabl
highthroughput
screen
herein
develop
multiplex
helicas
assay
base
graphen
oxid
go
highthroughput
screen
inhibitor
hcv
helicas
sever
acut
respiratori
syndrom
coronaviru
sar
cov
helicas
previous
report
gobas
helicas
assay
goha
reli
preferenti
bind
ssdna
dsdna
go
surfac
subsequ
quench
fluoresc
label
ssdna
energi
transfer
dye
go
valid
assay
use
sar
cov
helicas
herein
show
goha
use
measur
activ
hcv
helicas
sar
cov
helicas
singl
mix
solut
use
two
distinct
dna
substrat
tether
differ
fluorophor
furthermor
multiplex
highthroughput
screen
discov
highli
select
smallmolecul
inhibitor
helicas
figur
one
round
screen
chemic
librari
use
multiplex
goha
mgoha
reveal
three
class
inhibitorsspecif
inhibitor
hcv
helicas
specif
inhibitor
sar
cov
helicas
gener
inhibitor
helicas
date
go
use
develop
variou
biosensor
enzym
assay
concern
heterogen
chemic
structur
physic
dimens
go
nonspecif
bind
biomolecul
go
hamper
applic
gobas
assay
highthroughput
parallel
assay
drug
discoveri
requir
high
robust
reproduc
herein
show
go
use
discoveri
potent
smallmolecul
drug
candid
also
determin
specif
rel
effect
toward
helicas
identifi
hit
first
go
sheet
prepar
use
modifi
hummer
method
thick
prepar
go
sheet
nm
width
mm
determin
atom
forc
microscopi
afm
support
inform
figur
ir
spectrum
go
show
peak
cm
correspond
h
stretch
vibrat
co
stretch
vibrat
epoxi
vibrat
alkoxi
vibrat
figur
b
raman
spectrum
go
strong
dand
gband
absorpt
cm
respect
characterist
go
figur
c
collect
waterdispers
go
sheet
success
prepar
measur
orthogon
activ
sar
cov
hcv
helicas
either
helicas
ad
mixtur
go
two
dna
substratesa
dna
duplex
sar
cov
helicas
substrat
dna
duplex
hcv
helicas
substrat
figur
fluoresc
intens
correspond
exem
nm
exem
nm
show
littl
chang
without
addit
helicas
min
figur
addit
sar
cov
helicas
led
dramat
decreas
fluoresc
intens
fluoresc
intens
show
small
chang
suggest
dna
duplex
mainli
unwound
subsequ
interact
gener
ssdna
go
result
quench
fluoresc
figur
b
data
indic
unwind
activ
sar
cov
helicas
specif
correspond
dna
substrat
convers
addit
hcv
helicas
caus
signific
decreas
fluoresc
intens
assess
qualiti
mgoha
screen
zfactor
paramet
wide
use
evalu
robust
qualiti
screen
assay
determin
gener
highperform
assay
zfactor
higher
calcul
zfactor
ran
posit
neg
control
reaction
calcul
mean
c
posit
neg
control
respect
standard
deviat
c
use
equat
shown
figur
zfactor
mgoha
platform
sar
helicas
hcv
helicas
suggest
present
goha
better
robust
establish
assay
figur
f
plate
mgoha
use
screen
compound
librari
discov
inhibitor
sar
cov
helicas
hcv
helicas
figur
mixtur
librari
compound
helicas
prepar
ad
mix
solut
go
prepar
separ
primari
screen
librari
compound
helicas
substrat
use
concentr
mm
nm
nm
total
volum
ml
mixtur
incub
minut
fluoresc
measur
use
ivi
fluoresc
imag
system
figur
figur
posit
control
perform
helicas
absenc
librari
neg
control
exclud
helicas
compound
small
molecul
specif
inhibitor
sar
cov
helicas
hcv
helicas
found
compound
found
inhibit
helicas
inhibit
character
discov
inhibitor
quantit
evalu
inhibitori
effect
toward
respect
helicas
first
increas
fidel
data
elimin
fals
posit
hit
owe
poor
solubl
compound
perform
secondari
screen
replic
five
select
compound
primari
screen
total
compound
care
observ
reaction
mixtur
precipit
secondari
screen
select
toward
helicas
degre
inhibit
compar
primari
screen
compound
show
sever
precipit
exclud
final
select
final
select
mostpot
compound
includ
five
sar
cov
helicas
select
inhibitor
five
hcv
helicas
select
inhibitor
five
inhibitor
helicas
chemic
formula
select
compound
shown
figur
dosedepend
inhibit
sar
cov
helicas
hcv
helicas
measur
vari
concentr
inhibitor
use
goha
halfmaxim
inhibitori
concentr
ic
calcul
figur
antisarshel
antihcvhel
ic
valu
mm
mm
respect
found
higher
ic
valu
select
inhibitor
rang
mm
sar
cov
helicas
mm
hcv
figur
smallmolecul
screen
identifi
three
set
inhibitorsspecif
sar
cov
helicas
specif
hcv
helicas
nonspecif
helicas
inhibitor
top
repres
fluoresc
imag
primari
screen
carri
small
molecul
plate
signal
repres
inhibit
helicas
activ
sar
cov
hcv
respect
bottom
use
compound
select
initi
screen
secondari
screen
perform
quintupl
reveal
top
inhibitor
blue
bar
sarshel
red
bar
hcvhel
angewandt
zuschriften
helicas
previous
known
helicas
inhibitor
gener
exhibit
ic
valu
rang
mm
expect
structureact
relationship
sar
studi
could
optim
hit
goha
system
also
use
sar
studi
doserespons
data
fit
ic
curv
shown
figur
next
investig
mechan
inhibitori
effect
discov
compound
first
determin
whether
antisarshcvhel
bind
dsdna
low
select
two
type
helicas
might
come
nonspecif
bind
dsdna
thu
slow
unwind
process
howev
isotherm
titrat
calorimetri
itc
nmr
spectroscopi
show
interact
dsdna
figur
next
determin
whether
compound
inhibit
atpas
activ
helicas
figur
b
sarshel
hcvhel
possess
atpas
domain
catalyt
hydrolysi
atp
use
commerci
kit
analyz
atpas
activ
helicas
presenc
inhibitor
found
antisarshel
except
show
significantli
higher
inhibit
atpas
activ
sar
cov
helicas
hcv
helicas
antihcvhel
show
much
higher
inhibit
atpas
activ
hcv
helicas
sar
cov
helicas
block
atpas
activ
helicas
similar
degre
inhibit
atpas
activ
hcv
helicas
effect
sar
cov
helicas
howev
overal
inhibit
antisarshcvhel
atpas
activ
impress
antihcvhel
atpas
activ
hcv
helicas
inhibitor
select
helicas
could
block
atpas
activ
helicas
high
select
studi
perform
investig
mode
inhibitionwheth
inhibitor
bind
atp
bind
site
induc
conform
chang
alloster
regul
next
measur
inhibit
hcv
rna
replic
select
inhibitor
human
hepatoma
cell
line
carri
hcv
replicon
rna
luciferas
report
gene
replicon
cell
replicon
cell
treat
inhibitor
concentr
mm
lyse
luminesc
intens
measur
addit
luciferin
separ
cytotox
compound
measur
cell
line
use
mtt
assay
rel
luciferas
signal
intens
rel
mtt
signal
intens
luc
mtt
plot
versu
concentr
inhibitor
figur
see
figur
complet
data
luciferas
mtt
assay
two
compound
show
dosedepend
decreas
lucmtt
valu
respect
halfmaxim
effect
concentr
ec
ae
ae
mm
indic
dosedepend
block
hcv
rna
replic
cultur
cell
figur
b
c
decreas
luciferas
signal
mm
antihcvhel
compound
antisarshcvhel
highli
cytotox
show
less
cell
viabil
mm
show
littl
reduct
luciferas
signal
even
mm
exclud
rel
high
ec
mm
taken
togeth
block
hcv
rna
replic
cell
wherea
antisarshel
antisarshcvhel
show
appreci
inhibitori
effect
hcv
rna
replic
cultur
cell
result
show
helicas
inhibitor
specif
correspond
helicas
achiev
inhibitori
effect
live
cell
addit
nonselect
inhibitor
moder
reduc
activ
helicas
rel
high
cytotox
indic
compound
exclud
drug
develop
investig
whether
could
reduc
express
hcv
serin
proteas
block
hcv
rna
replic
cell
figur
cell
first
treat
mm
lucmtt
valu
respect
cell
viabil
base
mtt
assay
cell
lysi
hcv
serin
proteas
activ
measur
reson
energi
transfer
fret
peptid
substrat
treatment
reduc
proteas
activ
cell
untreat
cell
indic
serin
proteas
activ
also
decreas
result
inhibit
hcv
rna
replic
live
cell
conclus
demonstr
capabl
mgoha
assay
activ
two
helicas
hcv
sar
cov
appli
mgoha
highthroughput
inhibitor
screen
use
small
molecul
librari
yield
drug
candid
molecul
result
illustr
mgoha
import
screen
techniqu
drug
discoveri
target
helicas
goha
allow
figur
cellbas
assay
test
inhibit
hcv
rna
replic
liver
cell
luciferas
report
system
base
express
hcv
subgenom
cell
neomycin
antibiot
resist
marker
b
c
character
inhibit
hcv
rna
replic
live
cell
liver
cell
treat
inhibitor
luciferas
signal
intens
report
shown
divid
cell
viabil
plot
versu
inhibitor
concentr
correct
luciferas
signal
loss
cytotox
compound
confirm
two
inhibitor
block
hcv
rna
replic
thu
reduc
express
hcv
enzym
hcv
serin
proteas
activ
cell
lysat
measur
follow
incub
two
inhibitor
moreaccur
realtim
quantit
monitor
helicas
activ
simpli
follow
chang
fluoresc
intens
without
requir
addit
separ
step
trap
agent
multiplex
screen
highli
advantag
multipl
round
screen
combin
one
screen
reduc
overal
cost
labor
also
one
round
multiplex
screen
provid
inform
rel
select
hit
compound
toward
target
helicas
given
variou
gobas
activ
assay
develop
variou
enzym
includ
nucleas
methyltransferas
caspas
present
work
show
gobas
assay
use
highthroughput
screen
new
inhibitor
variou
essenti
enzym
treatment
hcv
infect
addit
directact
antivir
agent
like
inhibitor
proteas
standard
treatment
recent
approv
addit
multipl
drug
act
independ
viral
target
effect
control
infect
rapidli
mutat
viru
expect
new
inhibitor
hcv
helicas
discov
herin
could
use
antivir
drug
next
gener
hcv
treatment
three
activ
compon
addit
expect
goha
use
evalu
helicas
activ
highli
parallel
manner
helicaseinhibitorbas
drug
variou
diseas
difficult
without
robust
helicas
assay
receiv
novemb
publish
onlin
januari
keyword
biosensor
graphen
oxid
highthroughput
screen
helicas
multiplex
assay
